The US Food and Drug Administration proposed 3 September to restrict nine more active drug substances from being compounded in bulk by outsourcing facilities, saying these active substances already exist in dosage forms that are available in FDA-approved drug products.
This action may bolster predictions that the agency is accelerating its review and excluding more substances from compounding under Section...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?